IE990340A1 - A process for the preparation of aceclofenac - Google Patents

Abstract

Compound of the formula I (FORMULA) wherein R1, R2 and R3 are independently selected from lower alkyl groups C1-C4 or hydrogen, are particularly useful intermediates in producing Aceclofenac. The compounds are prepared by reacting Diclofenac acid with triethylamine, diisopropylamine or ammonia in a solvent at a temperature of from 20 degrees celcius to 60 degress celcius. The compounds of formula I are reacted with an appropriate x-haloacetic acid ester to form acetates which are deprotected to form Aceclofenac. x-Arylpropanoic Acid NSAID's may be prepared analogously.

Description

“A process for the preparation of Aceclofenac” Introduction The invention relates to a process for preparing non-steroidal anti-inflammatory 5 drugs, to intermediates used in the process, and processes for preparing such intermediates.

Aceclofenac (formula III) is one example of a non-steroidal anti-inflammatory drug (NSAID) with properties similar to Diclofenac. The gastrointestinal tolerability of Aceclofenac is better than that of Diclofenac and other NSAIDs and it has a faster onset of action (Drugs Vol. 52(1), 113-124 [1996]).

EP-A-119932 describes a process for preparing Aceclofenac by hydrogenation of benzyl-2-[(2,6-dichlorophenyl)amine] phenylacetoxyacetate with a palladium catalyst over a long period of time at severe reaction conditions. The 2-[(2,6dichlorophenyl)amine] phenylacetoxyacetate is prepared by dissolving the corresponding phenylacetate in DMF and reacting with benzyl bromoacetate.

ES-A-2020146 describes the preparation of Aceclofenac by treating corresponding 20 esters with iodine trimethylsilane which is prepared from chloromethylsilane and anhydrous sodium iodide in an inert atmosphere. Acetonitrile is used as the solvent. f1·-......................................... ί pjfy&ri'f A > 3 OPEN TO PUBLIC INSPECTION UNDER SECTION 28 AND RULE 23 JNL NQl OE CH-A-682747 describes a process for preparing Aceclofenac by acid hydrolysis of a 2-tetrahydropyranyl or 4-methoxy-4-tetrahydropyranyl ester. The esters are prepared by reacting the corresponding acetic acid with a corresponding haloacetate.

CA-A-2111169 describes phenylacetic acid derivatives and their salts. Sodium diclofenac is dissolved in DMF under a nitrogen atmosphere, the temperature is raised and tert.-butyl chloroacetate is added to yield tert.-butyl (2-(2,6dichloroaniline)phenyl) acetoxyacetate.

There are a number of problems with conventional processes for preparing Aceclofenac. The yield of at least some of the steps is low, the reaction time is relatively high, hazardous reaction conditions and/or solvents are required and/or the use of dipolar aprotic solvents such as DMF causes difficulties in purification of the final product.

There is therefore a need for an improved process for preparing Aceclofenac which will overcome at least some of these problems and thereby provide a process which is economic and viable on a commercial scale.

Statements of Invention The invention provides a compound of formula I wherein R‘, R2 and R3 are independently selected from lower alkyl groups (CrC4) or hydrogen.

Preferably R1, R2 and R3 are independently selected from one or more of ethyl and 5 isopropyl.

The invention also provides a process for preparing a compound of formula I by reacting 2-[(2,6-Dichlorophenyl)amine] phenylacetic Acid (Diclofenac Acid) with an appropriate amine of the formula NR’R2R3 wherein R1, R2 and R3 are as defined above.

The reaction may be carried out in a solvent selected from toluene, THF, acetone, MEK, MIBK, acetonitrile or a chlorinated solvent.

The formation of adduct I is carried out at a temperature of from 0° to 100°C, preferably from 20° to 60°C.

The amine may be triethylamine, diisopropylethylamine, or ammonia.

The invention also provides a process for preparing a compound of the formula II. by reacting a compound of formula I as defined above with an appropriate ahaloacetic acid ester, especially tert.-butyl-bromoacetate. In this case the substituent R4 is preferably tert.-butyl and the compound is tert.-butyl-2-[(2,6,dichlorophenyl) amine] phenylacetoxyacetate of the formula:- The invention further provides a process for preparing a compound of formula II as defined above with a deprotecting agent, especially formic acid or trifluoroacetic acid.

The invention also provides Aceclofenac whenever prepared by a process of the invention and/or using an intermediate of the invention.

Detailed description of the invention We have found that compounds of the general formula I are synthetically very useful compounds, especially as intermediates for producing 2-((2,6Dichlorophenyl)-amine]phenylacetoxyacetic acid (Aceclofenac).

Reaction Scheme Θ Compound I can be obtained in a simple process by reacting 2-((2,6Dichlorophenyl)amine]phenylacetic Acid (Diclofenac Acid) with an amine NR3R2R3. It was found that a variety of amines are suitable for the formation of adduct I. R1, R2 and R3 can independently be lower alkyl groups (C1-C4) or hydrogen, preferably ethyl and isopropyl. The solvents are toluene, THF, acetone, MEK, MIBK, acetonitrile or a chlorinated solvent and the adduct formation is carried out under very mild conditions of 0°-100°C, preferably 2060°C.

The ammonium salts of formula I can be reacted without isolation and purification directly with various α-haloacetic acid esters to give compounds of type II. The halogen substituent X can be Cl or Br, preferably Br. Group R4 is a lower alkyl substituent Ci-C4, preferably tert.-butyl. The reaction step is carried out in a temperature range of 20°-100°C, preferably 20°-60°C.

For the conversion of a compound of type II wherein R4 is tert.-butyl into 2-((2,6Dichlorophenyl)amine]phenyiacetoxyacetic Acid (Aceclofenac), formic acid and trifluoroacetic acid are suitable. The reaction can be carried out under very mild conditions 0°-100°C, preferably 20°-60°C.

The procedure for the preparation of 2-((2,6-dichlorophenyI)amine]phenylacetoxyacetic Acid (Aceclofenac) is a major improvement compared to known methods as the process is very simple. The reaction sequence can be carried out in either separate reaction steps or in a one pot process. The reaction time is relatively short and the reaction process is carried out without the use of heavy metal catalysts and hydrogen and/or difficult solvents. The product is obtained in high overall yield in very high purity under extremely mild reaction conditions.

Example 1 Preparation of taT.-Butyl-2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetate (method 1). 200 g (0.675 mol) of 2-[2,6-dichlorophenyl)amine]phenylacetic Acid were suspended in 800 ml of toluene at room temperature. 94 ml (0.675 mol) of triethylamine were added and the mixture was stirred until a clear solution was obtained. 109 ml (0.675 mol) of tert.-Butyl-bromoacetate were added. The mixture was heated to 40-60°C. After a reaction time of 3-4 hours 400 ml of water were added and the mixture was basified with 30% sodium hydroxide solution. The phases were separated and the organic layer was washed with water. The organic solvent was removed and the crude material purified with Petroleum Ether. Yield 76%.

‘H-NMR spectrum as attached (figure 1).

IR spectrum as attached (figure 2).

Microanalysis. calc.: C 58.54, H 5.12, N3.41; found: C 58.70, H 5.32, N 3.30.

Example 2 Preparation of tert. -Butyl-2-[(2,6-dichlorophenyl)amine] phenylacetoxyacetate (method 2). 100 g (0.338 mol) of 2-((2,6-Dichlorophenyl)amine]phenylacetic Acid were suspended in 300 ml of THF at room temperature. 58 ml (0.338 mol) of diisopropylethylamine were added and the mixture was stirred until a dear solution was obtained. 55 ml (0.338 mol) of tert.-Butyl-bromoacetate were added. The mixture was heated to 40-60°C. After a reaction time of 3-4 hours the mixture was basified with 30% sodium hydroxide solution. The phases were separated and the organic layer dried over sodium sulphate. The organic solvent was removed and the crude material purified with Petroleum Ether. Yield 64%.

Example 3 Preparation of Ammonium-2-[(2,6-dichlorophenyl)amine]phenylacetate. 100 g (0.338 mol) of 2-((2,6-Dichlorophenyl)amine]phenylacetic Acid were added to 300 ml of aqueous ammonia (25-30%). The mixture was heated to reflux and then cooled to room temperature to precipitate the product. The solid was filtered off and dried under vacuum. Yield 96 g (90%).

Example 4 Preparation of 2-((2,6-dichlorophenyl)amine]phenylacetoxyacetic Acid from tert.Butyl-2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetate (method 1). 260g (0.634 mol) of i Melting point 145°-149°C.

'H-NMR spectrum as attached (figure 3). 13C-NMR spectrum as attached (figure 4).

IR spectrum as attached (figure 5).

Microanalysis: calc.: C 54.26, H 3.67, N 3.95. found: C 54.40, H 3.69, N 3.88.

Example 5 Preparation of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic Acid from tert.Butyl-2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetate (method 2). g (0.024 mol) of tert.-Butyl-2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetate were stirred in 50 ml of a 1:1 mixture of trifluoroacetic acid and dichloromethane at a temperature of 0-30°C, preferably 15-20°C for 10-70 min, preferably 20-40 min. The solvent was removed and the product 2-((2,6dichlorophenyl)amine]phenylacetoxyacetic Acid precipitated by adding water. The crude material was recrystallised. Yield 79%.

Example 6 Preparation of 2-((2,6-dichlorophenyl)amine]phenylacetoxyacetic Acid in a one pot process. 800 g (2.70 mol) of 2-((2,6-Dichlorophenyl)amine]phenylacetic Acid were suspended in 3.2 litres of toluene at room temperature. 273 g (2.70 mol) of triethylamine were added and the mixture stirred until a clear solution was obtained. 480 ml (2.96 mol) of tert.-Butyl-bromoacetate were added. The mixture was heated to 40-60°C. After a reaction time of 3-4 hours the mixture was basified with 30% sodium hydroxide solution. The phases were separated and the organic layer was washed with water. The organic solvent was removed and 1.4 litres of formic acid were added. The mixture was stirred at 50-60°C, cooled to room temperature after approximately 30 min and diluted with water. The product was filtered off and purified with toluene. Overall yield 832 g (87%). ίο It is anticipated that the invention may be applied to other α-Arylpropanoic Acid NSAID’s. Analogous intermediates of structures I, II, and III above are also provided. The reaction scheme is analogous to that given above for Aceclofenac.

Some examples of α-Arylpropanoic Acid NSAID’s to which the invention can be applied include the following: feno.profen Indaprofen Carprofen Pelubiprofen The invention is not limited to the embodiments hereinbefore described which may be varied in detail.

Claims (1)

1. Claims 1. A compound of formula I wherein R 1 , R 2 and R 3 are independently selected from lower alkyl groups (C r C 4 ) or hydrogen. 10 2. A compound as claimed in claim 1 wherein R 1 , R 2 and R 3 are independently selected from one or more of ethyl and isopropyl. 3. A process for preparing a compound of formula I as defined in claim 1 by reacting 2-[(2,6-Dichlorophenyl)amine]phenylacetic Acid (Diclofenac 15 Acid) with an appropriate amine of the formula NR’R 2 R 3 wherein R 1 , R 2 and R 3 are as defined in claim 1. A process as claimed in claim 3 wherein the reaction is carried out in a solvent selected from toluene, THF, acetone, MEK, MIBK, acetonitrile or a chlorinated solvent. 5. 5. 5 6. 5 6. 7. ίο 8. 7. 8. 9. 10. 9. 10. A process as claimed in claim 3 or 4 wherein the adduct formation is carried out at a temperature of from 0 to 100°C, preferably from 20 to 60°C. A process as claimed in any of claims 3 to 5 wherein the amine is triethylamine. A process as claimed in any of claims 3 to 5 wherein the amine is diisopropylethylamine. A process as claimed in any of claims 3 to 5 wherein the amine is ammonia. A compound of formula I as defined in claim 1 whenever made by a process as claimed in any of claims 3 to 8. A process for preparing a compound of the formula II o 11. 11. wherein R 4 is lower alkyl by reacting a compound of formula I as defined in claim 1 wi± an appropriate α-haloacetic acid ester. A process as claimed in claim 10 wherein the halo group is Cl or Br. 12. A process as claimed in claim 10 or 11 wherein the halo group is Br. 13. A process as claimed in any of claims 10 to 12 wherein the a-haloacetic acid ester is tert.-Butyl-bromoacetate. 14. A process as claimed in any of claims 10 to 13 wherein R 4 is tert. Butyl. 15. A process as claimed in any of claims 10 to 14 wherein the reaction is carried out at a temperature of from 0 to 100°C, preferably 20 to 60°C. 16. A compound of formula Π as defined in claim 10 whenever made by a process as claimed in any of claims 10 to 15. 17. A process for preparing Aceclofenac by treating a compound of formula II as defined in claim 10 or 16 with a deprotecting agent. 18. A process as claimed in claim 17 wherein the deprotecting agent is formic acid. 19. A process as claimed in claim 17 wherein the deprotecting agent is trifluoroacetic acid. 20. A process for preparing Aceclofenac substantially as hereinbefore described with reference to the examples. 21. Aceclofenac whenever prepared by a process as claimed in any of claims 3 to 15 or claims 17 to 20. 22. A process for preparing a compound of formula I as defined in claim 1 substantially as hereinbefore described with reference to the examples. 23. 24. A process for preparing a compound of formula II as defined in claim 10 substantially as hereinbefore described with reference to the examples. A compound of the formula ίο 25. wherein R-COOH is an α-Arylpropanoic Acid NS AID. A compound of the formula o o 15 26. wherein R-COOH is an α-Arylpropanoic Acid NS AID and R 4 is Ci to C 4 alkyl. A process for preparing a chain extended α-Arylpropanoic Acid with an appropriate amine of the formula NR‘R 2 R 3 wherein R 1 , R 2 and R 3 are as defined in claim 1.